oncogenex pharmaceutical inc (OGXI) Key Developments
OncoGenex Pharmaceuticals, Inc. - Special Call
Apr 30 15
To discuss amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial
OncoGenex Regains Rights to Custirsen from Teva
Apr 27 15
OncoGenex Pharmaceuticals, Inc. announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva. The agreement between the two parties to terminate the collaboration includes a $23.2 million payment from Teva. This payment reflects a $27 million advance reimbursement amount less $0.8 million for expenses incurred by Teva in 2015 prior to the termination date as well as a $3 million holdback amount that may be used to settle additional expenses incurred by Teva related to the continued development of custirsen as well as certain indemnity claims. One half of the then remaining balance of the holdback amount will be released to OncoGenex in October 2015 with a further half of the then remaining amount paid in January 2016. Any final remaining amount will be released in April 2016. In addition, OncoGenex will take over responsibility for all custirsen expenses, including those related to the ENSPIRIT trial, as well as manufacturing and regulatory activities for custirsen programs that were previously managed by Teva.
OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Mar 26 15
OncoGenex Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $5.68 million, or $0.26 loss per share, compared to a net loss of $6.68 million, or $0.45 loss per share, for the same quarter ended December 31, 2013. Collaboration revenue was $5.65 million, compared to $8.6 million for the same quarter ended December 31, 2013.
For the year, the company reported net loss of $26.24 million, or $1.45 loss per share, compared to a net loss of $31.85 million, or $2.17 loss per share, for the year ended December 31, 2013. Collaboration revenue was $27.12 million, compared to $29.88 million for the year ended December 31, 2013.
OncoGenex Pharmaceuticals, Inc. Proposes Amendment to Certificate of Incorporation
Mar 25 15
OncoGenex Pharmaceuticals, Inc. announced that at the AGM to be held on May 21, 2015, the shareholders will consider amendment to certificate of incorporation to increase authorized shares of common stock from 50,000,000 to 75,000,000.
OncoGenex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:00 PM
Mar 25 15
OncoGenex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Scott Daniel Cormack, Founder, Chief Executive Officer, President, Treasurer, Secretary and Director.